125477

: Advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer, and hepatocellular carcinoma.

The number most prominently refers to BLA 125477 , the official Biologics License Application number for the FDA-approved drug Cyramza (ramucirumab) . Pharmaceutical Context (Cyramza) 125477

: Eli Lilly and Company (originally ImClone Systems LLC). metastatic non-small cell lung cancer